IL233454A - Bromodomain Inhibitors - Google Patents

Bromodomain Inhibitors

Info

Publication number
IL233454A
IL233454A IL233454A IL23345414A IL233454A IL 233454 A IL233454 A IL 233454A IL 233454 A IL233454 A IL 233454A IL 23345414 A IL23345414 A IL 23345414A IL 233454 A IL233454 A IL 233454A
Authority
IL
Israel
Prior art keywords
bromodomain inhibitors
bromodomain
inhibitors
Prior art date
Application number
IL233454A
Other languages
English (en)
Hebrew (he)
Other versions
IL233454A0 (en
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of IL233454A0 publication Critical patent/IL233454A0/en
Publication of IL233454A publication Critical patent/IL233454A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
IL233454A 2011-12-30 2014-06-29 Bromodomain Inhibitors IL233454A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2011/002224 WO2013097052A1 (en) 2011-12-30 2011-12-30 Bromodomain inhibitors
PCT/CN2012/086357 WO2013097601A1 (en) 2011-12-30 2012-12-11 Bromodomain inhibitors

Publications (2)

Publication Number Publication Date
IL233454A0 IL233454A0 (en) 2014-08-31
IL233454A true IL233454A (en) 2016-03-31

Family

ID=48696151

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233454A IL233454A (en) 2011-12-30 2014-06-29 Bromodomain Inhibitors

Country Status (40)

Country Link
US (6) US9296741B2 (enExample)
EP (2) EP2797918B1 (enExample)
JP (3) JP6117238B2 (enExample)
KR (1) KR102008975B1 (enExample)
CN (2) CN104136435B (enExample)
AR (2) AR089527A1 (enExample)
AU (3) AU2012361967B2 (enExample)
BR (1) BR112014016233B1 (enExample)
CA (1) CA2859619C (enExample)
CL (1) CL2014001752A1 (enExample)
CO (1) CO7020912A2 (enExample)
CR (1) CR20140332A (enExample)
CY (1) CY1120287T1 (enExample)
DK (1) DK2797918T3 (enExample)
DO (1) DOP2014000152A (enExample)
EC (1) ECSP14011359A (enExample)
ES (1) ES2665890T3 (enExample)
GT (1) GT201400133A (enExample)
HK (1) HK1258414A1 (enExample)
HR (1) HRP20180357T1 (enExample)
HU (1) HUE038391T2 (enExample)
IL (1) IL233454A (enExample)
LT (1) LT2797918T (enExample)
ME (1) ME03028B (enExample)
MX (1) MX341740B (enExample)
MY (1) MY172576A (enExample)
NO (1) NO2797918T3 (enExample)
PE (1) PE20142340A1 (enExample)
PH (1) PH12014501469B1 (enExample)
PL (1) PL2797918T3 (enExample)
PT (1) PT2797918T (enExample)
RS (1) RS56978B1 (enExample)
RU (3) RU2671571C1 (enExample)
SG (1) SG11201403717WA (enExample)
SI (1) SI2797918T1 (enExample)
TW (1) TWI602815B (enExample)
UA (1) UA111770C2 (enExample)
UY (2) UY34559A (enExample)
WO (2) WO2013097052A1 (enExample)
ZA (1) ZA201404616B (enExample)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX362384B (es) 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
SI2707361T1 (sl) 2011-05-10 2017-12-29 Gilead Sciences, Inc. Zlite heterociklične spojine kot modulatorji natrijevega kanala
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
ES2625945T3 (es) 2012-11-14 2017-07-21 Glaxosmithkline Llc Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
AU2014230816B9 (en) * 2013-03-14 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
CA2906100A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Treating th2-mediated diseases by inhibition of bromodomains
CA2903881C (en) 2013-03-15 2021-05-18 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2014191894A1 (en) 2013-05-27 2014-12-04 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
PT3004112T (pt) 2013-05-28 2017-12-11 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
CA2915622C (en) 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
MX365864B (es) 2013-06-21 2019-06-18 Zenith Epigenetics Ltd Inhibidores de bromodominio biciclicos novedosos.
EP3013828A4 (en) * 2013-06-28 2016-11-23 Abbvie Inc BROMDOMÄNENINHIBITOREN
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
EA201690087A1 (ru) 2013-07-31 2016-08-31 Зенит Эпидженетикс Корп. Новые квиназолиноны как ингибиторы бромодомена
HRP20221389T1 (hr) * 2013-10-18 2023-01-06 Celgene Quanticel Research, Inc. Inhibitori bromodomena
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
WO2015075665A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
US20150148372A1 (en) * 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081280A1 (en) * 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
AU2014363989A1 (en) * 2013-12-09 2016-06-16 Abbvie Inc. Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
EP3080132A4 (en) * 2013-12-10 2017-08-02 AbbVie Inc. Bromodomain inhibitors
WO2015092118A1 (en) * 2013-12-17 2015-06-25 Orion Corporation Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EP3099696A4 (en) 2014-01-31 2017-07-05 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2015117087A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2016134947A (ru) 2014-01-31 2018-03-01 Дана-Фарбер Кансер Институт, Инк. Производные диаминопиримидин бензолсульфона и их применение
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
JP6726658B2 (ja) * 2014-04-11 2020-07-22 イェン、ユンYEN, Yun ヒストン脱アセチル化酵素阻害剤
WO2015164480A1 (en) * 2014-04-23 2015-10-29 Incyte Corporation 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
US20150345047A1 (en) * 2014-05-29 2015-12-03 Memorial Sloan Kettering Cancer Center Systems and methods for identifying drug combinations for reduced drug resistance in cancer treatment
BR112017002190A2 (pt) 2014-08-08 2017-11-21 Dana Farber Cancer Inst Inc derivados de di-hidropteridinona e usos dos mesmos
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
US9527864B2 (en) 2014-09-15 2016-12-27 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
US10124009B2 (en) 2014-10-27 2018-11-13 Tensha Therapeutics, Inc. Bromodomain inhibitors
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (en) * 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
US9763922B2 (en) 2014-11-27 2017-09-19 Genentech, Inc. Therapeutic compounds and uses thereof
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
JP2017538721A (ja) 2014-12-17 2017-12-28 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメインの阻害剤
JP6709792B2 (ja) * 2015-01-29 2020-06-17 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
GB201503720D0 (en) * 2015-03-05 2015-04-22 Glaxosmithkline Ip No 2 Ltd Chemical compound
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016168565A1 (en) * 2015-04-16 2016-10-20 President And Fellows Of Harvard College Methods for treatment of chronic obstructive pulmonary disease and/or therapy monitoring
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180022992A (ko) * 2015-07-02 2018-03-06 오리온 코포레이션 브로모도메인 억제제로서 바이사이클릭 헤테로사이클 유도체
EP3334725B1 (en) * 2015-08-10 2025-04-23 Dana-Farber Cancer Institute, Inc. Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
CN108472300A (zh) 2015-09-11 2018-08-31 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
CN105254635A (zh) * 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
MX2018006499A (es) * 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
CN108602821B (zh) * 2015-12-14 2021-06-29 恒元生物医药科技(苏州)有限公司 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂
US20190040063A1 (en) * 2016-02-05 2019-02-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound for bromodomain-containing protein inhibitor and preparation pharmaceutical composition, and application thereof
WO2017142881A1 (en) 2016-02-15 2017-08-24 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
JP7037500B2 (ja) 2016-04-06 2022-03-16 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｍｄｍ２タンパク質分解剤
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
UA123168C2 (uk) 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
ES2793239T3 (es) * 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
EP3464286B1 (en) 2016-05-24 2021-08-18 Genentech, Inc. Pyrazolopyridine derivatives for the treatment of cancer
SMT202300155T1 (it) 2016-06-20 2023-07-20 Incyte Corp Forme solide cristalline di un inibitore di bet
JP7035027B2 (ja) 2016-09-13 2022-03-14 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン
CN110062759B (zh) 2016-09-13 2022-05-24 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
WO2018068283A1 (en) * 2016-10-14 2018-04-19 Abbvie Inc. Bromodomain inhibitors
EP3800182A1 (en) * 2016-10-14 2021-04-07 AbbVie Inc. Pyridin-2(1h)-one derivatives as bromodomain inhibitors
EP3539960A4 (en) 2016-11-10 2020-03-18 Luoxin Pharmaceutical (Shanghai) Co., Ltd. NITROGEN MACROCYCLIC COMPOUND, ITS PREPARATION METHOD, ITS PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
CN108069958A (zh) * 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
WO2018130174A1 (zh) * 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CN110198941B (zh) * 2017-01-25 2021-09-28 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
EP3577120A1 (en) 2017-02-03 2019-12-11 The Regents of The University of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
CN108627577A (zh) * 2017-03-17 2018-10-09 武汉宏韧生物医药科技有限公司 一种人血浆中小檗碱含量的定量检测方法
US20210130346A1 (en) * 2017-04-14 2021-05-06 Abbvie Inc. Bromodomain Inhibitors
WO2018223909A1 (zh) * 2017-06-05 2018-12-13 成都海创药业有限公司 一种嵌合分子及其制备和应用
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
CN109384785B (zh) * 2017-08-10 2021-09-28 浙江海正药业股份有限公司 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途
US11192865B2 (en) * 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
EP3741758A1 (en) 2018-01-16 2020-11-25 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Bromodomain inhibitor compound and use thereof
WO2019184919A1 (zh) * 2018-03-27 2019-10-03 成都海创药业有限公司 一种含有金刚烷的化合物及其在治疗癌症中的用途
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
AU2019268333A1 (en) * 2018-05-15 2020-10-29 Abbvie Inc. Treating solid tumors with bromodomain inhibitors
CN110577526B (zh) * 2018-06-07 2023-10-27 上海翰森生物医药科技有限公司 溴域结构蛋白抑制剂的盐及其制备方法和应用
CN110372693B (zh) * 2018-07-04 2022-05-03 清华大学 一种靶向降解bet蛋白的化合物及其应用
EP3828183A4 (en) 2018-07-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
CN110776508B (zh) 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
TWI816881B (zh) * 2018-09-13 2023-10-01 大陸商恒翼生物醫藥（上海）股份有限公司 用於治療三陰性乳癌之組合療法
WO2020092638A1 (en) * 2018-10-30 2020-05-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
CN111377934B (zh) * 2018-12-29 2023-01-24 中国科学院上海药物研究所 一类杂环化合物，其制备及用途
BR112021018372A2 (pt) * 2019-03-17 2021-11-23 Shanghai Ringene Biopharma Co Ltd Composto acilaminopirrolo-piridona, método para preparar o referido composto, composição farmacêutica e uso do mesmo
GB201905721D0 (en) * 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2020232214A1 (en) * 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
WO2021003310A1 (en) 2019-07-02 2021-01-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
CN114929703B (zh) * 2020-01-19 2025-03-28 正大天晴药业集团股份有限公司 一种溴区结构域蛋白抑制剂的晶型、盐型及其制备方法
CN119823124A (zh) 2020-03-05 2025-04-15 C4医药公司 用于brd9的靶向降解的化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN115667237A (zh) * 2020-07-17 2023-01-31 成都苑东生物制药股份有限公司 作为bet抑制剂的新型杂环化合物
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
JP2023538405A (ja) * 2020-12-01 2023-09-07 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 新規ｎ－複素環ｂｅｔブロモドメイン阻害剤、その調製方法及び医薬応用
EP4294382A4 (en) * 2021-02-18 2024-12-25 Merck Sharp & Dohme LLC Aryl ether compounds as tead modulators
WO2022258044A1 (zh) * 2021-06-11 2022-12-15 杭州中美华东制药有限公司 吡咯并吡啶酮类化合物及其制备方法和用途
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19
IL309651A (en) * 2021-06-29 2024-02-01 Tay Therapeutics Ltd History Pyrolopyridone is useful in the treatment of cancer
WO2023274418A1 (zh) * 2021-07-02 2023-01-05 南京明德新药研发有限公司 蛋白降解靶向嵌合体类化合物
CN115611890B (zh) * 2021-07-15 2024-05-31 成都硕德药业有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途
EP4460302A4 (en) * 2022-01-06 2025-12-24 Design Therapeutics Inc COMPOUNDS AND METHODS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
CN116554171B (zh) * 2022-05-30 2024-11-26 成都苑东生物制药股份有限公司 一种brd4抑制剂类化合物的晶型、用途及其制备方法
WO2024193527A1 (zh) * 2023-03-20 2024-09-26 山东新时代药业有限公司 作为溴结构域抑制剂的吡咯并[2,3-c]吡啶类化合物
WO2024220589A2 (en) * 2023-04-18 2024-10-24 Vyne Therapeutics Inc. Uses of pan bet inhibitors cross-reference to related applications
WO2024238871A1 (en) * 2023-05-18 2024-11-21 Rectify Pharmaceuticals, Inc. Aryl sulfonamide compounds and their use in treating medical conditions

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATA210876A (de) 1975-03-25 1979-01-15 Byk Gulden Lomberg Chem Fab Verfahren zur herstellung von neuen nidrofuryl- pyrazolderivaten
US4072746A (en) 1975-10-14 1978-02-07 Sterling Drug Inc. 3-Amino-5-(pyridinyl)-2(1H)-pyridinones
US4004012A (en) 1975-10-14 1977-01-18 Sterling Drug Inc. 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones
DE2845456A1 (de) 1978-10-19 1980-08-14 Merck Patent Gmbh 6-arylpyridazin-3-one und verfahren zu ihrer herstellung
US4298609A (en) 1979-08-30 1981-11-03 Sterling Drug Inc. 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents
FR2478640A1 (fr) 1980-03-24 1981-09-25 Sanofi Sa Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique
US4305943A (en) 1980-04-28 1981-12-15 Sterling Drug Inc. 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
US4486431A (en) 1981-01-14 1984-12-04 Sterling Drug Inc. Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones
US4337253A (en) 1980-04-28 1982-06-29 Sterling Drug Inc. 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic
US4338446A (en) 1980-04-28 1982-07-06 Sterling Drug Inc. Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates
US4304776A (en) 1980-04-28 1981-12-08 Sterling Drug Inc. 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics
US4346221A (en) 1980-04-28 1982-08-24 Sterling Drug Inc. Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones
US4559352A (en) 1981-03-30 1985-12-17 Sterling Drug Inc. 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4465686A (en) 1981-09-08 1984-08-14 Sterling Drug Inc. 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation
US4515797A (en) 1981-09-08 1985-05-07 Sterling Drug Inc. 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof
US4353905A (en) 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
US4599423A (en) 1982-04-26 1986-07-08 Sterling Drug Inc. Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
DE3321012A1 (de) 1983-06-10 1984-12-13 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
US4666902A (en) 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
GB8323553D0 (en) 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
US5192563A (en) 1986-10-22 1993-03-09 Wm. Wrigley, Jr. Company Strongly mint-flavored chewing gums with reduced bitterness and harshness
US5221543A (en) 1986-10-22 1993-06-22 Firma Wilhelm Fette Gmbh Method of making a fast release stabilized aspartame ingredient for chewing gum
US5217735A (en) 1986-10-22 1993-06-08 Wm. Wrigley Jr. Company Method of making chewing gum with delayed release ingredients
US5112625A (en) 1989-02-15 1992-05-12 Wm. Wrigley Jr. Company Aqueous zein coated sweeteners and other ingredients for chewing gum
US4863745A (en) 1986-10-22 1989-09-05 Wm. Wrigley Jr. Company Chewing gum containing zein coated high-potency sweetener and method
US4908371A (en) 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
US4919941A (en) 1987-12-18 1990-04-24 Wm. Wrigley Jr. Company Chewing gum containing delayed release protein sweetener and method
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU7238191A (en) 1990-02-19 1991-09-03 Chugai Seiyaku Kabushiki Kaisha Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom
DE4023369A1 (de) 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
ES2131506T3 (es) 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
EP0503079A4 (en) 1990-10-02 1992-10-28 Kaken Pharmaceutical Co., Ltd. Pyridazinone-substituted ethynylphenyl derivative and remedy for circulatory organ disease containing the same as active ingredient
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CN1038249C (zh) 1991-08-28 1998-05-06 罗姆和哈斯公司 含有二氢哒嗪酮及其相关化合物的杀菌组合物
US5716954A (en) 1991-10-09 1998-02-10 Syntex U.S.A. Inc. Benzopyridazinone and pyridopyridazinone compounds
NZ244660A (en) 1991-10-09 1995-05-26 Syntex Inc Pyridopyridazine derivatives and medicaments
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
EP0666851A4 (en) 1992-11-02 1995-08-30 Merck & Co. Inc. Substituted phthalazinones as nerotensin antagonists.
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JP3247540B2 (ja) 1994-05-12 2002-01-15 株式会社日立製作所 パケット化通信装置および切替え装置
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
JPH08337583A (ja) * 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
JPH11508267A (ja) 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
AU723064B2 (en) 1995-08-25 2000-08-17 Dow Agrosciences Llc Compositions having synergistic fungitoxic effects
KR100338144B1 (ko) 1996-09-13 2002-05-24 가마쿠라 아키오 티에노트리아졸로디아제핀 화합물 및 그의 약제학적 용도
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
PT984961E (pt) 1997-04-01 2001-11-30 Astrazeneca Ab Novos derivados de piridina e composicoes farmaceuticas que os contem
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
AU738595B2 (en) 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
SK8402000A3 (en) 1997-12-05 2001-03-12 Astrazeneca Uk Ltd Novel compounds
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6365589B1 (en) * 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
JP3910365B2 (ja) 1998-07-16 2007-04-25 塩野義製薬株式会社 抗腫瘍活性を有するピリミジン誘導体
US6271380B1 (en) * 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
CN1297916A (zh) 1999-11-26 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸
DE10010423A1 (de) 2000-03-03 2001-09-06 Bayer Ag Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung
CN1315397A (zh) 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸
AU5696800A (en) 2000-07-04 2002-01-14 Robert John Eyre Harvesting machine
JP2003313169A (ja) 2002-04-19 2003-11-06 Otsuka Chemical Holdings Co Ltd ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR100985160B1 (ko) * 2002-06-06 2010-10-05 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합된 이미다졸 유도체
WO2004014384A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
SE527371C2 (sv) * 2003-04-24 2006-02-21 Volvo Lastvagnar Ab Hjulupphängning för fordon samt fordon försett med sådan hjulupphängning
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
CN1812981A (zh) 2003-06-27 2006-08-02 万有制药株式会社 杂芳氧基含氮饱和杂环衍生物
DE602004025258D1 (de) 2003-08-06 2010-03-11 Vertex Pharma Aminotriazol-verbindungen als proteinkinase-hemmer
CN1870896A (zh) 2003-10-20 2006-11-29 默克公司 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
SG115845A1 (en) 2004-03-31 2005-10-28 Univ Singapore Modulation of trip-br function and method of treating proliferative disorders
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
US20080090827A1 (en) 2004-11-30 2008-04-17 Artesian Therapeutics, Inc. Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
JPWO2006059778A1 (ja) 2004-12-01 2008-06-05 萬有製薬株式会社 置換ピリドン誘導体
AU2006223236A1 (en) 2005-03-14 2006-09-21 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
WO2007008144A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008145A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
ES2380236T3 (es) 2005-10-28 2012-05-09 Takeda Pharmaceutical Company Limited Compuesto de amida heterocíclica y uso del mismo
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US8247414B2 (en) 2006-07-25 2012-08-21 Cephalon, Inc. Pyridizinone derivatives and the use thereof as H3 inhibitors
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
SG178786A1 (en) 2006-11-13 2012-03-29 Lilly Co Eli Thienopyrimidinones for treatment of inflammatory disorders and cancers
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
JP5470557B2 (ja) 2007-07-26 2014-04-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ES2499017T3 (es) 2007-10-23 2014-09-26 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
WO2009054790A1 (en) 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8476260B2 (en) 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
US8242111B2 (en) 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
KR20110002492A (ko) 2008-05-01 2011-01-07 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
CA2723034A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
KR20110050459A (ko) 2008-07-25 2011-05-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
WO2010127237A2 (en) 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
HRP20120992T1 (hr) 2008-11-20 2012-12-31 Merck Sharp & Dohme Corp. Aril metil benzokinazolinon kao pozitivni alosterni modulatori receptora m1
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
ES2539964T3 (es) 2009-11-05 2015-07-07 Glaxosmithkline Llc Procedimiento novedoso
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MX2012005295A (es) 2009-11-05 2012-06-19 Glaxosmithkline Llc Inhibidor de bromodominio de benzodiazepina.
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
US9102677B2 (en) 2009-11-05 2015-08-11 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US20130061612A1 (en) 2009-11-11 2013-03-14 E.I. Du Pont De Nemours And Company Refrigerant storage in secondary loop refrigeration systems
MX362384B (es) * 2010-05-14 2019-01-15 Dana Farber Cancer Inst Inc Composiciones y metodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos.
US9085582B2 (en) * 2010-06-22 2015-07-21 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP2757887B1 (en) * 2011-09-22 2017-04-26 VIIV Healthcare UK Limited Pyrrolopyridinone compounds and methods for treating hiv
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
CN104334526A (zh) * 2012-04-20 2015-02-04 艾伯维公司 异吲哚酮衍生物
RU2632915C2 (ru) * 2012-06-12 2017-10-11 Эббви Инк. Производные пиридинона и пиридазинона
EP3013828A4 (en) * 2013-06-28 2016-11-23 Abbvie Inc BROMDOMÄNENINHIBITOREN

Also Published As

Publication number Publication date
ES2665890T3 (es) 2018-04-30
GT201400133A (es) 2015-09-17
SG11201403717WA (en) 2014-07-30
AU2012361967A1 (en) 2014-07-03
EP3360874A1 (en) 2018-08-15
NZ725267A (en) 2018-04-27
US20210236508A1 (en) 2021-08-05
CN104136435B (zh) 2017-05-10
PH12014501469A1 (en) 2014-10-08
LT2797918T (lt) 2018-03-26
JP6371430B2 (ja) 2018-08-08
RU2647592C2 (ru) 2018-03-16
UY39630A (es) 2022-03-31
MY172576A (en) 2019-12-03
CO7020912A2 (es) 2014-08-11
DOP2014000152A (es) 2014-08-31
CA2859619C (en) 2022-01-04
JP2017128594A (ja) 2017-07-27
US20180296566A1 (en) 2018-10-18
CN106986872B (zh) 2020-04-21
PT2797918T (pt) 2018-03-07
NO2797918T3 (enExample) 2018-04-28
AU2012361967B2 (en) 2017-09-07
MX2014008143A (es) 2014-11-25
US9296741B2 (en) 2016-03-29
HK1203511A1 (en) 2015-10-30
KR20140113704A (ko) 2014-09-24
RU2671571C1 (ru) 2018-11-02
ECSP14011359A (es) 2015-09-30
CN104136435A (zh) 2014-11-05
SI2797918T1 (en) 2018-05-31
US20230158039A1 (en) 2023-05-25
RU2014131378A (ru) 2016-02-20
JP6117238B2 (ja) 2017-04-19
MX341740B (es) 2016-08-31
UY34559A (es) 2013-07-31
IL233454A0 (en) 2014-08-31
EP2797918A1 (en) 2014-11-05
AR125222A2 (es) 2023-06-28
ME03028B (me) 2018-10-20
HRP20180357T1 (hr) 2018-04-06
TWI602815B (zh) 2017-10-21
CA2859619A1 (en) 2013-07-04
PL2797918T3 (pl) 2018-05-30
TW201339158A (zh) 2013-10-01
BR112014016233A8 (pt) 2017-07-04
EP2797918B1 (en) 2017-11-29
PH12014501469B1 (en) 2019-01-25
JP2018172428A (ja) 2018-11-08
AU2017219100C1 (en) 2019-05-16
AR089527A1 (es) 2014-08-27
CL2014001752A1 (es) 2014-10-10
BR112014016233B1 (pt) 2020-04-28
KR102008975B1 (ko) 2019-08-08
CR20140332A (es) 2014-11-10
US20250152600A1 (en) 2025-05-15
WO2013097052A1 (en) 2013-07-04
UA111770C2 (uk) 2016-06-10
EP2797918A4 (en) 2015-07-01
US20140162971A1 (en) 2014-06-12
US20160143916A1 (en) 2016-05-26
CN106986872A (zh) 2017-07-28
CY1120287T1 (el) 2019-07-10
AU2019203939A1 (en) 2019-06-20
RU2018137194A (ru) 2020-04-23
DK2797918T3 (en) 2018-03-12
ZA201404616B (en) 2015-12-23
RS56978B1 (sr) 2018-05-31
WO2013097601A1 (en) 2013-07-04
BR112014016233A2 (pt) 2017-06-13
AU2017219100B2 (en) 2019-01-31
HUE038391T2 (hu) 2018-10-29
HK1203508A1 (en) 2015-10-30
AU2017219100A1 (en) 2017-09-14
PE20142340A1 (es) 2015-02-07
JP2015503529A (ja) 2015-02-02
HK1258414A1 (en) 2019-11-08

Similar Documents

Publication Publication Date Title
IL233454A0 (en) Bromodomain inhibitors
IL228707A0 (en) History of tetrahydroquinolines used as bromodomain inhibitors
PL2710007T3 (pl) Inhibitory kinazy
ZA201404156B (en) Kinase inhibitors
GB201118784D0 (en) Djml
EP2755962A4 (en) AZAINDAZOLES
EP2736330A4 (en) COMPOUNDS AND METHODS
IL229028A0 (en) Kinase inhibitors
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
EP2736329A4 (en) COMPOUNDS AND METHODS
ZA201404157B (en) Kinase inhibitors
IL235919A0 (en) inhibitors of fbxo3
GB201115617D0 (en) Proacess
DK2770906T3 (en) Applanationstonometer
GB201103110D0 (en) An insert
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
GB201106941D0 (en) An insert
GB201104426D0 (en) PhilharmonicLights_b
GB201018597D0 (en) Inhibitors
GB201102977D0 (en) Cyclobuggy
GB201102052D0 (en) Stabilearner
GB201102013D0 (en) Aimspray easyreach
GB201101772D0 (en) Hat-Pack

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed